[제약/바이오(Overweight) 다올 제약/바이오 이지수☎2184-2363]

[제약/바이오(Overweight) | 다올 제약/바이오 이지수☎2184-2363] ★ 바이오시밀러 9월 미국 처방 실적 ▶ Infliximab 점유율(IV시장 기준): Remicade 47.0%, Inflectra 30.6%, Renflexis 10.8%, Avsola 11.7% (수량 기준) ▶ Remicade 52.6%, Inflectra 32.0%, Renflexis 9.0%, Avsola 6.5% (금액 기준) *Institutional 기준으로 retail은 제외한 수치 ▶ Rituximab 점유율: Rituxan 23.3%, Truxima 39.1%, Ruxience 32.4%, Riabni 5.2% (수량 기준) ▶ Rituxan 26.7%, Truxima 40.3%, Ruxience 28.4%, Riabni 4.5% (금액 기준) ▶ Trastuzumab 점유율: Herceptin 9.4%, Kanjinti 33.7% Ogivri 21.5%, Trazimera 24.7%, Herzuma 7.3%, Ontruzant 3.4% (수량 기준) ▶ Herceptin 12.7%, Kanjinti 39.8%, Ogivri 17.5% Trazimera 19.1%, Herzuma 6.9%, Ontruzant 3.9% (금액 기준) ▶ Bevacizumab 점유율: Avastin 12.4%, Mvasi 57.5%, Zirabev 23.9%, Vegzelma 6.2% (수량 기준) ▶ Avastin 11.2%, Mvasi 59.7%, Zirabev 22.5%, Vegzelma 6.5% (금액 기준) ▶ Adalimumab 점유율: Humira 0.0%, Humira CF 41.7%, Hadlima 19.0% Hyrimoz 14.5%, Amjevita 4.2%, Clytezo 7.3%, Yuflyma 11.4%, Hulio 0.7%, Yusimry 0.8%, Idacio 0.3% (수량 기준) ▶ Adalimumab 점유율: Humira 0.1%, Humira CF 81.4%, Hadlima 5.3% Hyrimoz 5.4%, Amjevita 1.6%, Clytezo 2.6%, Yuflyma 3.2%, Hulio 0.2%, Yusimry 0.2%, Idacio 0.2% (금액 기준) ▶ Ranibizumab 점유율: Lucentis 76.0%, Byooviz 2.9%, Cimerli 24.0% (수량 기준) ▶ Lucentis 94.6%, Byooviz 2.4%, Cimerli 3.1% (금액 기준) ▶ Ustekinumab 점유율: Stelara SC 27.5% Stelara IV 0.1%, Wezlana 1.9%, Steqeyma 16.4%, Pyzchiva 6.9%, Selarsdi 10.0%, Yesintek 35.5%, Imuldosa 0.3%, Otulfi 1.4% (수량 기준) ▶ Ustekinumab 점유율: Stelara SC 74.8% Stelara IV 1.2%, Wezlana 1.5%, Steqeyma 5.9%, Pyzchiva 2.8%, Selarsdi 4.0%, Yesintek 9.2%, Imuldosa 0.1%, Otulfi 0.5% (금액 기준) ★ 보고서원문 및 컴플라이언스 →